Nefopam and Morphine Consumption in the Treatment of Ureteral Calculi
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00639574|
Recruitment Status : Completed
First Posted : March 20, 2008
Last Update Posted : March 29, 2010
The administration of néfopam after initial treatment by kétoproféne, could obtain, in patients remaining pain and classically need morphine, analgesia at least the same as morphine alone. The use of néfopam second line after ketoprofen could reducing (or even eliminating) the need for morphine (and its side effects), allowing a reduction in the length of stay of patients in the emergency unit.
The main objective is to show that the addition of a néfopam initial treatment with the kétoproféne, reduces, in patients with ureteral calculi, the percentage of patients requiring the use of a treatment by morphine.
The secondary objective is to reduce the side effects caused by the morphine, shorten the time to install the appropriate level of analgesia while reducing the risk of failure of the titration morphine, reduce the time spent on titration of morphine and reduce the length of stay patient intake in emergency unit.
|Condition or disease||Intervention/treatment||Phase|
|Ureteral Calculi, Hyperalgic, Not Complicated||Drug: Néfopam||Phase 4|
The study is prospective, parallel, double-blind, randomized, placebo-controlled analysis with intent to treat. There are 2 groups:
- A group N: néfopam
- A group P: placebo And all the patient receive, before randomization, 100 mg of ketoprofen (Profenid ®) on 20 minutes.
The number of subjects is 52.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||52 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Interest of Néfopam in the Treatment of Pain During the Intense Ureteral Calculi Uncomplicated in Adults in Emergencies Unit.|
|Study Start Date :||March 2008|
|Actual Primary Completion Date :||November 2008|
|Actual Study Completion Date :||September 2009|
- Drug: Néfopam
There are two groups :
- a group N : néfopam
- a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes.
- Need to use morphine as an analgesic scheme (binary yes/no) [ Time Frame: As analgesic scheme ]
- Quantity of morphine consumed after titration (mg and number of bolus) [ Time Frame: After titration and after administration of placebo or néfopam ]
- Pain (measured by the EVA) after administration of placebo or néfopam [ Time Frame: After titration and after administration of placebo or néfopam ]
- Simplified verbal Scale of Satisfaction [ Time Frame: After titration and after administration of placebo or néfopam ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00639574
|Clermont-Ferrand, France, 63003|
|Principal Investigator:||Moustafa Fares, Dr||University Hospital, Clermont-Ferrand|